DNA SYNTHESIZER MARKET ANALYSIS

Market News

Recent Developments

New product launches

• SYNTAX DNA Printing Platform System (DNA Script, 2023): DNA Script, the worldwide leader in Enzymatic DNA Synthesis (EDS) technology, announced the broad commercial availability of the fully automated SYNTAX DNA printing platform, which consists of the benchtop STX-200 system, the latest biochemistry advancements, robust reagent kits, and intuitive software enhancements.
• InfiniSynth Platform (Ribbon Biolabs GmbH, 2022): Ribbon Biolabs GmbH, the DNA synthesis company, announced the successful implementation of their innovative InfiniSynth platform for the automated assembly of sequence-agnostic and long DNA. Ribbon Biolabs achieved this milestone in collaboration with HighRes Biosolutions, a leading laboratory automation technology company. The InfiniSynth platform enables Ribbon Biolabs to enter the market in 2023 with a highly differentiated approach to providing critical tools for life science research and biopharmaceutical development.
• ENFINIA (Elegen Corporation, 2023): Elegen Corporation, a leader in DNA innovation, announced that it has successfully concluded its early access program and is now offering global commercial access to its new class of double-stranded DNA, developed to power the synthetic biology revolution. Elegen’s ENFINIA DNA represents a major advance in the field, offering an unprecedented combination of length, speed, and accuracy to streamline synthetic biology workflows and scale to meet the demands of the growing bioeconomy.

Acquisition, Partnerships, and Funding

• On July 4, 2023, Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, closed a US$10mn Series A financing round. The new funding will be used to scale operations and continue the development of its DNA synthesis platform.
• On January 9, 2023, Twist Bioscience Corporation, a public biotechnology company, announced a partnership with Astellas Pharma, a Japan multinational pharmaceutical company, seeking to discover antibodies against several targets to hit on curative therapies for hard-to-treat diseases. Twist Biosciences focuses on synthetic biology and genomics company to develop a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a technology for manufacturing synthetic DNA by “writing” DNA on a silicon chip. Under the terms of the agreement, Twist will conduct antibody discovery activities against multiple targets identified by Astellas. Besides upfront payment and project-specific research fees, Twist will be eligible to receive up to US$ 11 million per product through payments associated with defined clinical and commercial milestones.
• In October 2022, DNA Script, a world leader in enzymatic DNA synthesis (EDS) for DNA on demand, signed distribution agreements in the Middle East with Gulf Scientific Corporation, a leading provider of complete laboratory solutions across the Middle East and Eisenberg Ltd., and Israel scientific instrument company, to expand its worldwide footprint of sales, service, and support. A new distribution partner, Kiko Tech, Ltd., a Japan analytical, medical and life science provider company, extends the company’s existing channel network in the Asia-Pacific (APAC) region.
• In May 2022, DNA Script reached a distribution agreement with Premas Life Sciences, a biotechnology research company, which announced to expand DNA Script’s footprint and provide sales and support for the SYNTAX System DNA printer in labs in India. The SYNTAX System printer is the only commercial DNA manufacturing technology that utilizes the power of enzymatic DNA synthesis (EDS), which produces synthetic DNA without the toxic reagents and hazardous waste associated with older DNA printing methods.
• In January 2022, Ribbon Biolabs, the DNA synthesis company, announced the successful close of EUR 18 million in its Series A funding round from a consortium of European and US investors led by Hadean Ventures, and with participation from Lansdowne Partners, Helicase Venture as well as several undisclosed investors. Existing investors IST cube and TECNET equity also joined in the round.